Y
Yoshiharu Sakai
Researcher at Kyoto University
Publications - 440
Citations - 14680
Yoshiharu Sakai is an academic researcher from Kyoto University. The author has contributed to research in topics: Cancer & Colorectal cancer. The author has an hindex of 53, co-authored 428 publications receiving 11525 citations. Previous affiliations of Yoshiharu Sakai include Ehime University & Osaka University.
Papers
More filters
Journal ArticleDOI
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer
Toshiaki Watanabe,Michio Itabashi,Yasuhiro Shimada,Shinji Tanaka,Yoshinori Ito,Yoichi Ajioka,Tetsuya Hamaguchi,Ichinosuke Hyodo,Masahiro Igarashi,Hideyuki Ishida,Megumi Ishiguro,Yukihide Kanemitsu,Norihiro Kokudo,Kei Muro,Atsushi Ochiai,Masahiko Oguchi,Yasuo Ohkura,Yutaka Saito,Yoshiharu Sakai,Hideki Ueno,Takayuki Yoshino,Takahiro Fujimori,Nobuo Koinuma,Takayuki Morita,Genichi Nishimura,Yuh Sakata,Keiichi Takahashi,Hiroya Takiuchi,Osamu Tsuruta,Toshiharu Yamaguchi,Masahiro Yoshida,Naohiko Yamaguchi,Kenjiro Kotake,Kenichi Sugihara,Rectum +34 more
TL;DR: The English version of the JSCCR Guidelines 2016 is presented, which can be used as a tool for treating colorectal cancer in actual clinical practice settings and as a guide to obtaining informed consent from patients and choosing the method of treatment for each patient.
Journal ArticleDOI
Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer
Toshiaki Watanabe,Michio Itabashi,Yasuhiro Shimada,Shinji Tanaka,Yoshinori Ito,Yoichi Ajioka,Tetsuya Hamaguchi,Ichinosuke Hyodo,Masahiro Igarashi,Hideyuki Ishida,Soichiro Ishihara,Megumi Ishiguro,Yukihide Kanemitsu,Norihiro Kokudo,Kei Muro,Atsushi Ochiai,Masahiko Oguchi,Yasuo Ohkura,Yutaka Saito,Yoshiharu Sakai,Hideki Ueno,Takayuki Yoshino,Narikazu Boku,Takahiro Fujimori,Nobuo Koinuma,Takayuki Morita,Genichi Nishimura,Yuh Sakata,Keiichi Takahashi,Osamu Tsuruta,Toshiharu Yamaguchi,Masahiro Yoshida,Naohiko Yamaguchi,Kenjiro Kotake,Kenichi Sugihara +34 more
TL;DR: The English version of the JSCCR Guidelines 2014 can be used as a guide to obtaining informed consent from patients and choosing the method of treatment for each patient, and can, therefore, be used for treating colorectal cancer in clinical practice.
Journal ArticleDOI
Age-related remodelling of oesophageal epithelia by mutated cancer drivers
Akira Yokoyama,Nobuyuki Kakiuchi,Tetsuichi Yoshizato,Yasuhito Nannya,Hiromichi Suzuki,Yasuhide Takeuchi,Yusuke Shiozawa,Yusuke Sato,Kosuke Aoki,Soo Ki Kim,Yoichi Fujii,Kenichi Yoshida,Keisuke Kataoka,Masahiro Nakagawa,Yoshikage Inoue,Tomonori Hirano,Yuichi Shiraishi,Kenichi Chiba,Hiroko Tanaka,Masashi Sanada,Yoshitaka Nishikawa,Yusuke Amanuma,Shinya Ohashi,Ikuo Aoyama,Takahiro Horimatsu,Shin'ichi Miyamoto,Shigeru Tsunoda,Yoshiharu Sakai,Maiko Narahara,J.B. Brown,Yoshitaka Sato,Genta Sawada,Koshi Mimori,Sachiko Minamiguchi,Hironori Haga,Hiroshi Seno,Satoru Miyano,Hideki Makishima,Manabu Muto,Seishi Ogawa,Seishi Ogawa +40 more
TL;DR: In physiologically normal epithelia, age-related expansion of clones that carry mutations in NOTCH1 and other driver genes is accelerated by risk factors for developing oesophageal squamous cell carcinoma, such as alcohol consumption or smoking.
Journal ArticleDOI
Dclk1 distinguishes between tumor and normal stem cells in the intestine
Yuki Nakanishi,Hiroshi Seno,Ayumi Fukuoka,Taro Ueo,Yuichi Yamaga,Takahisa Maruno,Naoko Nakanishi,Keitaro Kanda,Hideyuki Komekado,Mayumi Kawada,Akihiro Isomura,Kenji Kawada,Yoshiharu Sakai,Motoko Yanagita,Ryoichiro Kageyama,Yoshiya Kawaguchi,Makoto Mark Taketo,Shin Yonehara,Tsutomu Chiba +18 more
TL;DR: It is shown here that Dclk1 does not mark NSCs in the intestine but instead marks TSCs that continuously produce tumor progeny in the polyps of ApcMin/+ mice, suggesting the potential for developing a therapy for colorectal cancer based on targeting D clk1-positive T SCs.
Journal ArticleDOI
Involvement of vascular endothelial growth factor receptor-3 in maintenance of integrity of endothelial cell lining during tumor angiogenesis.
Hajime Kubo,Takashi Fujiwara,Takashi Fujiwara,Takashi Fujiwara,Lotta Jussila,Lotta Jussila,Lotta Jussila,Hiroyuki Hashi,Hiroyuki Hashi,Hiroyuki Hashi,Minetaro Ogawa,Minetaro Ogawa,Minetaro Ogawa,Kenji Shimizu,Kenji Shimizu,Kenji Shimizu,Masaaki Awane,Masaaki Awane,Masaaki Awane,Yoshiharu Sakai,Yoshiharu Sakai,Yoshiharu Sakai,Arimichi Takabayashi,Arimichi Takabayashi,Arimichi Takabayashi,Kari Alitalo,Kari Alitalo,Kari Alitalo,Yoshio Yamaoka,Yoshio Yamaoka,Yoshio Yamaoka,Shin-Ichi Nishikawa,Shin-Ichi Nishikawa,Shin-Ichi Nishikawa +33 more
TL;DR: It is demonstrated that the inactivation of VEGFR-3 by a novel blocking monoclonal antibody (mAb) suppresses tumor growth by inhibiting the neo-angiogenesis of tumor-bearing tissues and suggests that the VEGF-C/VEG FR-3 pathway may serve another candidate target for cancer therapy.